Country: United States
Language: English
Source: NLM (National Library of Medicine)
HUMAN IMMUNOGLOBULIN G (UNII: 66Y330CJHS) (HUMAN IMMUNOGLOBULIN G - UNII:66Y330CJHS)
Baxalta US Inc.
HUMAN IMMUNOGLOBULIN G
HUMAN IMMUNOGLOBULIN G 50 ug in 1 mL
Biologic Licensing Application
GAMMAGARD S/D- HUMAN IMMUNOGLOBULIN G BAXALTA US INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE GAMMAGARD S/D SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR GAMMAGARD S/D GAMMAGARD S/D, IMMUNE GLOBULIN INTRAVENOUS (HUMAN) IGA LESS THAN 1 MICROGRAM PER ML IN A 5% SOLUTION INITIAL U.S. APPROVAL: 1994 WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING_ ▪ ▪ ▪ RECENT MAJOR CHANGES Warnings & Precautions, Aseptic Meningitis Syndrome (5.4) 09/2016 INDICATIONS AND USAGE GAMMAGARD S/D is an Immune Globulin Intravenous (Human) indicated for: ▪ ▪ ▪ ▪ DOSAGE AND ADMINISTRATION INTRAVENOUS USE ONLY * INDIC ATIO N RECOMMENDED DOSAGE DURATIO N PI (2.1) 300-600 mg/kg Every 3 to 4 weeks CLL (2.2) 400 mg/kg Every 3 to 4 weeks ITP (2.3) 1g/kg Maximal 3 doses on alternate days Kawasaki Syndrome (2.4) Single 1g/kg or 400 mg/kg for 4 consecutive days Begin within 7 days of onset of fever DOSAGE FORMS AND STRENGTHS ▪ CONTRAINDICATIONS ▪ THROMBOSIS MAY OCCUR WITH IMMUNE GLOBULIN PRODUCTS, INCLUDING GAMMAGARD S/D. RISK FACTORS MAY INCLUDE ADVANCED AGE, PROLONGED IMMOBILIZATION, HYPERCOAGULABLE CONDITIONS, HISTORY OF VENOUS OR ARTERIAL THROMBOSIS, USE OF ESTROGENS, INDWELLING VASCULAR CATHETERS, HYPERVISCOSITY AND CARDIOVASCULAR RISK FACTORS. (5.3) RENAL DYSFUNCTION, ACUTE RENAL FAILURE, OSMOTIC NEPHROSIS, AND DEATH MAY OCCUR IN PREDISPOSED PATIENTS WITH IMMUNE GLOBULIN INTRAVENOUS (IGIV) PRODUCTS, INCLUDING GAMMAGARD S/D. RENAL DYSFUNCTION AND ACUTE FAILURE OCCUR MORE COMMONLY WITH IGIV PRODUCTS CONTAINING SUCROSE. GAMMAGARD S/D DOES NOT CONTAIN SUCROSE. (5.2) FOR PATIENTS AT RISK OF THROMBOSIS, ADMINISTER GAMMAGARD S/D AT THE MINIMUM DOSE AND INFUSION RATE PRACTICABLE. ENSURE ADEQUATE HYDRATION IN PATIENTS BEFORE ADMINISTRATION. MONITOR FOR SIGNS AND SYMPTOMS OF THROMBOSIS AND ASSESS BLOOD VISCOSITY IN PATIENTS AT RISK OF HYPERVISCOSITY. (5.3) Treatment of prim Read the complete document